Drug Profile

Research programme: wee1 kinase inhibitors - Schrodinger

Alternative Names: SDGR2; SDGR2-WEE1; Wee1 program

Latest Information Update: 28 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Schrodinger
Class Antineoplastics
Mechanism of Action WEE1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Gynaecological cancer
No development reported Solid tumours

Most Recent Events

28 Jun 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
03 Nov 2022 Schrodinger is on track to select a Wee1 development candidate, in the first half of 2023
03 Nov 2022 Schrodinger announces intention to submit IND application to the US FDA for Solid tumours in USA, in the first half of 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com